Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 5/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.36 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.33 |
| ▸ | TNKS | O95271 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20971823 | 0.83 | GPR119 (0.52) | GPR119 | |
| SCHEMBL20897979 | 0.82 | BTK (0.43) | BTKGAACYP2C9CYP2C19MAPK14 | |
| SCHEMBL28291346 | 0.76 | MEN1 (0.33) | BTK | |
| SCHEMBL1816284 | 0.73 | PARP10 (0.36) | BTKGAACYP2C9PARP1 | |
| SCHEMBL5266309 | 0.69 | PARP14 (0.51) | GAATNKSPARP1PARP14 | |
| SCHEMBL15566612 | 0.68 | BRD9 (0.32) | MAPK14 | |
| SCHEMBL17276048 | 0.67 | ATM (0.39) | ITGB3ITGA2B | |
| SCHEMBL20897951 | 0.67 | L3MBTL1 (0.45) | — | |
| SCHEMBL23022739 | 0.66 | ATM (0.51) | CYP2C9CYP2C19MAPK14 | |
| SCHEMBL12631540 | 0.66 | CYP2C9 (0.56) | CYP2C9GPR119PARP14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109661392-A | For treating the mitochondrial inhibitors of proliferative disorder | 巴斯利尔药物国际股份公司 | 2019-04-19 | — | — | CN | disclosed |